^
    1d
    Dara-RVd Induction for Newly Diagnosed Multiple Myeloma With Autologous Stem Cell Transplantation (clinicaltrials.gov)
    P2, N=0, Withdrawn, UNC Lineberger Comprehensive Cancer Center | N=39 --> 0 | Suspended --> Withdrawn
    Enrollment change • Trial withdrawal
    |
    lenalidomide • bortezomib • Darzalex (daratumumab) • dexamethasone
    2d
    AQUILA: A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma (clinicaltrials.gov)
    P3, N=390, Completed, Janssen Research & Development, LLC | Active, not recruiting --> Completed
    Trial completion
    |
    Darzalex Faspro (daratumumab and hyaluronidase-fihj)
    2d
    Forimtamig: a potent GPRC5D-targeted bispecific antibody in multiple myeloma. (PubMed, Ann Med Surg (Lond))
    When combined with standard agents such as daratumumab, pomalidomide, or cereblon E3 ligase modulatory drugs, forimtamig has shown improved tumor clearance and reduced relapse rates. Currently undergoing phase 1 trials, forimtamig is being evaluated both as monotherapy and in combination regimens. Its high potency, favorable safety, and durable immune engagement make it a promising candidate in the evolving treatment landscape of multiple myeloma.
    Journal
    |
    CRBN (Cereblon)
    |
    Darzalex (daratumumab) • pomalidomide • forimtamig (RG6234)
    5d
    A Study of Daratumumab (clinicaltrials.gov)
    P3, N=500, Recruiting, Janssen Research & Development, LLC | Trial completion date: Jan 2029 --> Dec 2029
    Trial completion date
    |
    lenalidomide • Darzalex (daratumumab) • carfilzomib • pomalidomide • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • dexamethasone injection
    5d
    SCILLA: Self-administered Subcutaneous Daratumumab in Patients With Multiple Myeloma (clinicaltrials.gov)
    P4, N=50, Not yet recruiting, Odense University Hospital | Trial completion date: Jun 2027 --> Jan 2028 | Initiation date: Jan 2026 --> Aug 2026 | Trial primary completion date: Dec 2026 --> Jun 2027
    Trial completion date • Trial initiation date • Trial primary completion date
    |
    Darzalex Faspro (daratumumab and hyaluronidase-fihj)
    5d
    TRANSCEND: A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated Rejection (AMR) (clinicaltrials.gov)
    P3, N=132, Active, not recruiting, Biogen | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    felzartamab (MOR202)
    5d
    AQUARIUS: A Study of Daratumumab-Based Therapies in Participants With Amyloid Light Chain (AL) Amyloidosis (clinicaltrials.gov)
    P2, N=151, Active, not recruiting, Janssen Research & Development, LLC | Trial primary completion date: May 2025 --> Feb 2026
    Trial primary completion date
    |
    bortezomib • cyclophosphamide • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • dexamethasone injection
    7d
    SKylaRk: KRDI in Transplant-Eligible MM (clinicaltrials.gov)
    P2, N=50, Active, not recruiting, Massachusetts General Hospital | Trial completion date: Mar 2026 --> Dec 2026
    Trial completion date
    |
    lenalidomide • carfilzomib • Sarclisa (isatuximab-irfc)
    8d
    CEPHEUS: A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy (clinicaltrials.gov)
    P3, N=395, Completed, Janssen Research & Development, LLC | Active, not recruiting --> Completed
    Trial completion
    |
    lenalidomide • bortezomib • dexamethasone • Darzalex Faspro (daratumumab and hyaluronidase-fihj)
    8d
    Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma (clinicaltrials.gov)
    P2, N=50, Recruiting, UNC Lineberger Comprehensive Cancer Center | Trial completion date: Mar 2031 --> May 2033 | Trial primary completion date: Mar 2026 --> May 2033
    Trial completion date • Trial primary completion date
    |
    lenalidomide • dexamethasone • Sarclisa (isatuximab-irfc)
    10d
    2023/ABM/01/00072: A study aimed at Optimise and Personalise Immunological Therapy of relapsed chronic lymphocytic leukaemia patients (OPTIC) (2024-513917-11-01)
    P1/2, N=36, Not yet recruiting, Uniwersytet Medyczny W Lublinie
    New P1/2 trial
    |
    Venclexta (venetoclax) • Gazyva (obinutuzumab) • Darzalex (daratumumab)
    12d
    First-in-human Single Agent Study of SAR442257 in RRMM and RR-NHL (clinicaltrials.gov)
    P1, N=47, Completed, Sanofi | Active, not recruiting --> Completed
    Trial completion • First-in-human
    |
    BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
    |
    SAR442257